Cambrex Corporation, the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), announced that it has completed the installation of multiple continuous flow reactor platforms at its High Point, North Carolina, US facility.
The investment underpins Cambrex’s on-going commitment to new technologies and aims to reinforce the company’s existing experience in continuous flow. This latest investment in continuous flow will focus on the rapid and successful development of processes to supply clinical as well as commercial demand for chemical syntheses.
The investment in developmental capabilities builds upon the recent expansions made at the commercial-scale in the dedicated continuous flow production unit, at the Karlskoga, Sweden facility, which is capable of producing multiple metric tons of high purity intermediates per annum.
The new development center at High Point will be led by Dr. Shawn Conway, who has joined Cambrex as Director of Engineering R&D. With extensive experience in both pilot and commercial scale continuous processing, Dr. Conway will be supported by a team of chemical engineers.
The continuous flow development center is the latest investment at Cambrex’s High Point site which has recently seen the completion and qualification of a new analytical laboratory and a pilot plant expansion with a reactor capacity of 4,000 liters.
Cambrex, a global leading CDMO, offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and continuous processing.